Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | PRKACA | P17612 | 1/20 | 0.49 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.49 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.49 |
| ▸ | PRKX | P51817 | 1/20 | 0.49 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.49 |
| ▸ | PRKG2 | Q13237 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.49 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.49 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.49 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.49 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31750709 | 1.00 | ATM (0.54) | ATMPPARGPPARAROCK2PRKACA | |
| SCHEMBL18589398 | 1.00 | ATM (0.54) | ATMPPARGPPARAROCK2PRKACA | |
| SCHEMBL12765837 | 0.89 | ATM (0.52) | ATMPPARGPPARAGAAMME | |
| SCHEMBL5757441 | 0.88 | ATM (0.53) | ATMPPARGPPARAGAAMME | |
| SCHEMBL18589373 | 0.88 | ATM (0.53) | ATMPPARGPPARAGAAMME | |
| SCHEMBL18607994 | 0.88 | ATM (0.53) | ATMPPARGPPARAGAAMME | |
| SCHEMBL14885608 | 0.87 | ATM (0.48) | ATMPPARGPPARAROCK2PRKACA | |
| SCHEMBL21676555 | 0.87 | ATM (0.55) | ATMPPARGPPARAACEAPP | |
| SCHEMBL6479279 | 0.87 | CTSS (0.57) | ATMPPARAAPPCTSSCTSK | |
| SCHEMBL6479218 | 0.87 | CTSS (0.57) | ATMPPARAAPPCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12325701-B2 | YKL-40 inhibitors and their therapeutic | MOLECURE S.A. (PL) | 2025-06-10 | — | — | US | disclosed |
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-09-07 | — | — | US | disclosed |
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-09-07 | — | — | US | disclosed |
| US-20190345137-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | GALAPAGOS NV (BE) | 2019-11-14 | — | — | US | disclosed |
| US-10208020-B2 | Substituted amino triazoles useful as human chitinase inhibitors | Oncoarendi Therapeutics S.A. (PL) | 2019-02-19 | — | — | US | disclosed |
| EP-3344616-B1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | ONCOARENDI THERAPEUTICS SA (PL) | 2019-01-09 | — | — | EP | disclosed |
| US-9944624-B2 | Substituted amino triazoles useful as human chitinase inhibitors | Oncoarendi Therapeutics S.A. (PL) | 2018-04-17 | — | — | US | disclosed |
| US-9944624-B2 | Substituted amino triazoles useful as human chitinase inhibitors | Oncoarendi Therapeutics S.A. (PL) | 2018-04-17 | — | — | US | disclosed |
| US-20170066743-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | GALAPAGOS NV (BE) | 2017-03-09 | — | — | US | disclosed |
| US-20170066743-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | GALAPAGOS NV (BE) | 2017-03-09 | — | — | US | disclosed |
| WO-2017037670-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | OncoArendi Therapeutics Sp. z o.o. (PL) | 2017-03-09 | — | — | WO | disclosed |
| EP-1149076-B1 | O-THIOCARBAMOYL-AMINOALKANOL COMPOUNDS, THEIR PHARMACEUTICALLY ACCEPTABLE SALTS AND PROCESS FOR PREPARING THE SAME | SK CORP (KR) | 2003-10-22 | — | — | EP | disclosed |
| EP-1149076-A1 | O-THIOCARBAMOYL-AMINOALKANOL COMPOUNDS, THEIR PHARMACEUTICALLY ACCEPTABLE SALTS AND PROCESS FOR PREPARING THE SAME | SK Corporation (KR) | 2001-10-31 | — | — | EP | disclosed |
| WO-2000046191-A1 | O-THIOCARBAMOYL-AMINOALKANOL COMPOUNDS, THEIR PHARMACEUTICALLY ACCEPTABLE SALTS AND PROCESS FOR PREPARING THE SAME | SK CORPORATION (KR) | 2000-08-10 | — | — | WO | disclosed |
| US-5935997-A | O-thiocarbamoyl-aminoalkanol compounds, their pharmaceutically useful salts and process for preparing the same | YUKONG LIMITED (KR) | 1999-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345137-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | CHIA, CHIT1, AADAC | ATM 707/4885PPARG 3255/4885PPARA 3785/4885 |
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | CHI3L1, CHI3L2, CHIA | ATM 2618/4885PPARG 4776/4885PPARA 4708/4885 |
| US-12325701-B2 | YKL-40 inhibitors and their therapeutic | CHI3L1, CHI3L2, CHIA | ATM 2548/4885PPARG 4735/4885PPARA 4651/4885 |
| US-10208020-B2 | Substituted amino triazoles useful as human chitinase inhibitors | CHIA, CHIT1, AADAC | ATM 707/4885PPARG 3255/4885PPARA 3785/4885 |
| US-20170066743-A1 | SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS | CHIA, CHIT1, AADAC | ATM 707/4885PPARG 3255/4885PPARA 3785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.